Incyte to Host Webcast at 2010 ACR/ARHP Annual Scientific Meeting

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) announced that it has scheduled a webcast for 8:00 p.m. ET today, Wednesday, November 10, 2010 to review the INCB28050 Phase II results being presented today at 5:30 p.m. ET during the 2010 ACR/ARHP Annual Scientific Meeting in Atlanta.

The live webcast can be accessed by going to our website at under Investor Relations, Events and Webcasts. A replay of the webcast will also be available following the event.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology and inflammation. For additional information on Incyte, visit the Company's web site at


Incyte Corporation
Pamela M. Murphy
Vice President, Investor Relations & Corporate Communications

KEYWORDS:   United States  North America  Delaware  Georgia

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical



Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.